Genome-wide association analysis is emerging as a powerful tool to define novel genes and molecular pathways involved in susceptibility to human complex disorders. However, in spite of recent successes, this approach is not without its limitations, the most notable of which is inconsistent phenotype penetrance due to varied environmental exposures. Mouse models do, however, circumvent some of these drawbacks by allowing for a much higher degree of control over genetic variation and environmental exposure, and although their application to human complex genetics is not always straightforward, they do serve as a powerful means of complementing observations in human populations. Mouse quantitative trait locus mapping has proven a successful, yet technically demanding method for defining trait susceptibility. In this review, we focus upon recent advances that are both reducing the technical burden traditionally associated with quantitative trait locus mapping, and enhancing the applicability of these approaches to human disease.
INTRODUCTION
Advances in genomic technologies have heralded a new era in genetic analysis of common diseases. Most recently this has been demonstrated by the advent of microarraybased platforms that allow researchers to genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) within a single individual. This capability has enabled a number of groups to perform whole-genome association studies that have identified SNPs associated with a variety of common diseases such as breast cancer (13) , prostate cancer (63) , colorectal cancer (64) , type 1 and 2 diabetes (20, 44, 47, 59) , Crohn disease (42, 59), celiac disease (51), and restless leg syndrome (60) . As a result, our understanding of the underlying genetic variants that play a role in establishing susceptibility for many common clinical disorders has been significantly increased. Furthermore, the identification of novel genes and/or molecular pathways involved in disease susceptibility has opened additional avenues of research that continue to give us greater insight into the pathological basis of complex disorders.
As further advances in genotyping and sequencing reduce the costs of these studies, many more exciting results will undoubtedly follow. Much focus has thus deservedly been placed on these studies. However, like all research strategies and methods, whole-genome association analyses suffer from intrinsic limitations and cannot give us a complete insight into the complex genetic and environmental interactions associated with common disease phenotypes. No single strategy has ever been able to completely encompass all the components and factors necessary to provide a comprehensive understanding of disease etiology, particularly not in the enormously complex arena of human polymorphism, population dynamics, and environmental exposures. The continuing development of mouse models, tools, resources, and methodologies should therefore remain a prominent parallel strategy by which to investigate the genetic and environmental components involved in human disease susceptibility. In this review we briefly discuss the advances in quantitative trait locus (QTL) analysis over the past decade, primarily by using mouse cancer models as an example. We then attempt to illustrate how mouse QTL and whole-genome association analyses are actually complementary approaches that can serve to enhance our understanding of the genetic basis of human disease.
WHOLE-GENOME ASSOCIATION ANALYSIS
With the current flood of whole-genome association papers demonstrating the power of this approach, a very relevant and pertinent question is, why continue the development of mouse susceptibility genetics? The answer to this question essentially lies in consideration of those inherent limitations of whole-genome association analysis that prevent capture of all relevant biological information. For example, it is known that cancer susceptibility is the result of an interaction between constitutional genetic factors and varying environmental exposures. However, the effects of genetic variants may only be detectable in those individuals with the appropriate environmental exposures. For instance, substantial environmental contributions to breast cancer susceptibility appear to result from dietary (32) and reproductive factors (5), alcohol consumption (45), as well as other exposures. Inability to account for such variables in whole-genome association studies may reduce the power of analyses or obscure the ability to identify true causative susceptibility loci (2) .
A further complication is that of population substructure. Differing levels of relatedness among individuals or undetected subpopulations are potent sources of both false-negative and false-positive outcomes in whole-genome association analyses (48). Furthermore, this issue will likely become increasingly important in future studies given that larger sample sizes, assembled from multiple different populations, will be required to detect the substantially more modest effects of those loci not captured in first-generation association studies. In addition, replication of the initial results will become increasingly more challenging if successively larger sample sizes are needed to detect significant associations.
In addition, although a number of associations have been detected for genes with the most potent phenotypic effects (13, 24, 33, 37, 54, 61) , most disease susceptibility is probably not due to a collection of genes with additive effects. Rather there are likely a number of genes that modulate susceptibility primarily through nonadditive interactions. These interactions can be multiplicative or conditional interactions, where the main effect of one gene is dependent on the presence of a particular allele of a second locus. Identification of these causative polymorphisms poses a significant problem for a variety of reasons. First, while a single SNP requires the analysis of 3 genotype classes, analysis of 2 SNPs requires the characterization of 9 different 2-locus combinations, 3 SNPs 27 genotype classes, and so on (34). This "curse of dimensionality" (4) may rapidly exceed the number of individuals who can be recruited into epidemiological studies to provide sufficient statistical power to detect associations (34). Furthermore, if SNPs do not have effects independent of interactions, then analyzing hundreds of thousands of SNPs in pairwise or higher-order fashion will undoubtedly exceed currently available computational capacity (34).
MOUSE MODELS OF COMPLEX DISEASE: A COMPLEMENTARY APPROACH
Mouse models, despite their limitations, provide a means of circumventing at least some of the limitations of human whole-genome association studies. There is growing evidence in the literature demonstrating that genetic susceptibility plays a very similar role in complex disease pathogenesis in both humans and in mouse models in spite of interspecies differences. An example of a complex trait mapping to the same genes or orthologous regions in the mouse and human genome includes plasma concentrations of high-density lipoprotein cholesterol, an imComplex trait: a trait that develops through interaction of a number of genes with environmental factors. This type of inheritance is common in human disease and is referred to as polygenic inheritance portant determinant of atherosclerotic vascular disease (57) . In this case, the mouse and human experiments have provided complementary clues for each system during the analysis (46), or mouse QTLs have been demonstrated to translate into human disease susceptibility loci (8, 9, 14, 15) . These successes suggest that the development of mouse complex trait analysis should be continued in parallel with the further investigation of human complex disease susceptibility. Indeed, utilization of these complementary approaches may well facilitate the development of novel methodologies and resources to help unravel the extremely complex interwoven factors affecting disease etiology.
Technological Advances Aid QTL Identification
What is the current status of modeling genetic susceptibility in the mouse? The difficulties reported to be associated with QTL mapping in the mouse have caused many investigators to explore alternative strategies for candidate gene identification (36). Specifically, the lack of mapping resolution and the difficulty of identifying genes, much less appropriate candidate genes, significantly impaired the ability of complex trait genetics to reach the "end game," i.e., the identification of specific susceptibility gene(s) for any given trait. Fortunately, technical advances in the interim have significantly alleviated many of these difficulties. The completion of the human (30, 52) and mouse (58) genome sequencing projects, the preeminent technical advances, made it possible for the first time to identify all genes within a given region of interest. This in turn has allowed for the targeted development of reagents to analyze specific candidate genes without the laborious and timeconsuming genomic screening previously required to simply identify potential transcripts.
Our ability to identify and characterize candidate regions has continued to expand dramatically as additional species have been sequenced (for examples, see 6, 27, 31 enabled direct visualization of SNPs among many of the commonly used inbred mouse strains by the use of chip-based sequencing and large-scale polymorphism screening (17) . Furthermore, sequence availability across species has permitted further acceleration of candidate gene identification for those traits that have been mapped in multiple species. Identification of orthologous chromosomal segments and their breakpoints in genetically defined candidate regions can help refine QTL localization and candidate gene lists by limiting searches to those loci shared between the two species (12) . The most successful application of this approach to date has been the identification of a number of loci associated with cholesterol metabolism (56) . A further advantage of the flood of sequence information is the ability to analyze haplotype structure, which was originally developed in human genetic mapping (53). Knowledge of those segments of the genome that are identical by descent (i.e., have the same haplotype structure) between mouse strains is a valuable method of refining regions of interest. Use of partially inbred mouse strains (14) or multiple genetic mapping studies with different inbred strain combinations can rapidly reduce the number of candidate genes that need to be screened for effects (14, 38, 55) .
In addition to sequence information, other technologies have also significantly contributed to the ability to sort through QTL candidate lists. One of the most commonly used is genome-wide expression arrays. The observation that most SNPs lie outside of coding regions has led many to hypothesize that most QTLs are likely due to subtle changes in gene expression rather than to missense or nonsense mutations. This suggestion has subsequently led to the screening of genetically defined candidate intervals for genes that display differential expression between the strains of interest (3). This approach, originally designated genetical-genomics (28) , provides an unbiased method for rapidly screening through hundreds of potential candidate genes simultaneously to reduce the list for further analysis to a manageable number (12, 22) .
Advances in computing technology have enhanced our understanding of haplotype structure both in humans and model organisms, and the combination of human epidemiological association studies and haplotype analysis can also be a powerful tool for the screening, identification, and characterization of candidate QTLs. Reduction of candidate regions to relatively small intervals, followed by screening of potential genes using haplotype-tagged SNPs in appropriate human cohorts, can provide direct evidence of potential pathological roles in human disease and also give important clues into the identity of candidates in mouse systems (8, 9, 14) . When appropriate human cohorts exist, this strategy can be a very efficient and rapid method for screening genomic regions, requiring significantly less time and effort than development of new in vitro systems or the generation of specialized mouse models.
Novel QTL Mapping Strategies Enhance Our Understanding of Human Disease
Ultimately, the efficiency of QTL modeling in the mouse is dependent upon good genetic mapping resolution. This has been, and continues to be, the major roadblock to efficient identification of novel modifier genes. Like other forms of complex trait analysis, recent innovations are beginning to alleviate some of the more problematic aspects of this area. Standard backcross and intercross genetic mapping suffers from the inability to refine candidate intervals much below half-chromosome resolution. To address this shortcoming, new genetic mapping strategies have been developed. Recombinant congenics (11) and advanced intercross panels (10), for example, reduce the amount of donor genome interrogated in each member of these specialized mapping panels, thus increasing resolution (see Figure 1) . The trade-off is an increased amount of breeding over standard mapping strategies. An alternative strategy is to use multiple mapping crosses with different combination of strains to identify common haplotype blocks that segregate within the genetically defined candidate regions to narrow down the search for genes of interest (22, 23, 38, 55) . Initial higher mapping resolutions can be achieved by use of heterogeneous stock mice (35). These mice are generated from the random breeding of progeny originating from typically four to eight inbred strains. Random segregation over many generations of breeding results in large numbers of meiotic crossovers, which is essentially the genomic equivalent of what is observed in outbred human populations. The greater frequency of meiotic crossovers therefore necessitates high-resolution genotyping to capture the information of interest, which in turn allows traits of interest to be mapped at a high resolution. The downside of this strategy is again increased breeding requirements, as well as much more extensive genotyping.
A major shortcoming of most genetic mapping strategies to date is the fact that each animal produced during the meiotic mapping process is genetically unique. However, biological replicates provide an important source of statistical power for identification of candidate genes in most experimental strategies in systems biology. In addition, to date, unique mapping populations have had to be developed for each investigator's phenotype of interest. This has precluded the ability to investigate, at least with any degree of ease, how similar genetic variation influences what on the face may seem to be unrelated phenotypes of interest. However, as our computational abilities expand to enable better modeling of the complex interwoven networks that underlie all biological processes, it will be a significant advantage to directly assay more and more complex traits on the same genetic backgrounds to determine how genetic variation affects the entire organism, as well as to provide a virtually unlimited amount of tissues for future experimental investigation.
The Collaborative Cross-A Powerful New Tool for Complex Trait Analysis
To combine the high-resolution mapping capacity of heterogeneous stock animals with the "immortal" and easily replicable properties of inbred strains, an effort has recently been undertaken to develop a new mapping resource that can be utilized by many different laboratories as a genetic reference panel. Known as the Collaborative Cross, the project aims to develop a large panel of new recombinant inbred lines derived from eight different inbred mouse strains (7, 49, 50) . Using a defined breed-
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Figure 2
Simplified schematic representation of the Collaborative Cross breeding strategy. An example of a breeding funnel is shown, with each of the eight progenitor inbred strains represented by a different color. The genomes of all eight progenitors are mixed by controlled breeding in the G0-G3 generations, followed by inbreeding. Multiple independent funnels are breeding simultaneously, with different independent permutations of the starting positions of the inbred progenitors, resulting in production of a series of genetically complex recombinant inbred strains (other funnels represented by light gray arrows).
ing scheme and high-density genotyping, the phase and origin of each genomic segment will be known (Figure 2) . Sufficient meiotic recombination will be incorporated across the panel to enable much higher resolution mapping of quantitative traits. Since the RI panel will be completely inbred, it will be possible to generate virtually unlimited amounts of material for current, and future, in vitro, in vivo, and genomic analytical methods. Furthermore, as investigators analyze new phenotypes on the panel, it will be possible to start understanding the complex networks of interacting phenotypes by directly comparing the data accumulated on the same set of genetically segregating genotypes.
The Collaborative Cross will also help address another significant shortcoming of using the mouse to model human populations, that of genetic diversity. Due to the relatively low number of progenitors for the common laboratory inbred strains, large regions of the genome are identical by descent (IBD). For pairwise comparisons between any two common laboratory strains, IBD has been estimated to vary between 36% to 62% percent (62) . As a result, large genetic "holes" exist that preclude the ability to screen significant portions of the genome. In addition, because of the number of strains included in the Collaborative Cross, including members of the three major mouse subspecies, almost 90% of the genetic variation present in the mouse genome will be available for screening, with similar minor allele frequency as observed in the human population (43).
The Practical Application of Complex Trait Analysis in Mouse Models to Human Disease
The evolution of complex trait strategies is enabling greater and faster analysis and identification of complex traits with higher intricacy. Mouse models permit the inclusion of genetically sensitized strains to address specific, focused but previously unexplored questions. For example, by using the highly metastatic polyoma middle T (PyMT) antigen transgene model, it was demonstrated that mammary tumor metastasis, which was thought to be the result of somatic evolution (16) , actually has a significant inherited susceptibility component (25, 39) . Further studies have demonstrated that these results translate into the human population. Pilot molecular epidemiological association studies of the human orthologs of the metastasis modifiers Sipa1 (39) and Rrp1b (8) have shown statistically significant associations PyMT: polyoma middle T (9) . In addition, these results have prompted reexamination of clinical data in a descriptive epidemiology study that discovered an increased risk of metastatic disease in the first-degree relatives of probands who had died within five years of diagnosis (21) .
Metastasis:
These relatively straightforward complex trait analyses have recently been further extended by the investigation of additional factors thought to significantly contribute to human cancer progression, diet and obesity. Introduction of an obesity-sensitive strain, M16i (1), as the mapping partner for the PyMT animal, and a high-fat diet, has enabled direct experimental evaluation of these known factors for human breast cancer progression (29) . These experiments demonstrated that, as expected, high-fat diets lead to a more malignant tumor phenotype (18, 19) . In addition, a number of associated genetic loci were identified, providing the initial dissection of the underlying genetic contributions. Furthermore, current complex trait strategies are enabling investigation of not only gene-environment interactions, but also of epigenetic contributions to phenotypes. For example, utilization of the compound Trp53-Nf1 knockout mouse model demonstrated that not only did both glioblastoma (40) and astrocytoma (41) have inherited components, but significant epigenetic events might also play an important role in disease pathogenesis (41).
CONCLUSION: FUTURE PROBLEMS
In spite of the clinical importance of the examples discussed above, it is difficult to envision an easy and efficient analysis of such complex interactions in human populations. First, it is virtually impossible to control important covariates such as environmental exposure in human populations. Second, to address the types of questions posed by these types of complex interactions, it becomes necessary to stratify patients into increasingly smaller and more homogenous subgroups. Association studies performed in such undersized subcohorts subsequently suffer from a substantial reduction in www.annualreviews.org • The Future of Mouse QTL Mappingstatistical power to the point where significant numbers of false negatives might rob investigators of a more comprehensive understanding of the disease phenotypes and molecular pathways that underpin them. Mouse models, however, provide a parallel platform for direct experimentation to confirm the results of human epidemiology and association studies. Furthermore, we will probably see an increasing sophistication of mouse models in the very near future. This will likely lead not only to the development of clinically relevant disease models but also to increasingly informative genetic analyses that augment observations from humanbased studies. In addition, and more important, it provides a vehicle in which to identify key genes and molecular pathways that may evade capture by current capabilities in human wholegenome association studies. The continued integration of these approaches, with each species informing the biology of the other, will result in a richer comprehension of the diverse and immense complexity of cancer and other disease phenotypes, which in turn will likely lead to significant improvements in clinical management of human disease.
SUMMARY POINTS
1. Whole-genome association analysis is a powerful means of elucidating novel susceptibility loci for complex human disorders.
2. Whole-genome association studies are not, however, without their limitations. These inherent constraints reduce the power of this type of analysis to detect novel susceptibility loci.
3. Mouse models of human disease provide a particularly useful complement to wholegenome association analysis. Quantitative trait locus analysis is an increasingly powerful tool in this respect, and recent technological innovations in this area have improved their applicability to human disease.
4. Novel QTL mapping strategies like the Collaborative Cross are enhancing our understanding of human disease.
5. A number of recent studies have illustrated the relevance of complex trait analysis in mouse models to human disease.
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